论文部分内容阅读
在证实分子改进能增强人绒毛膜促性腺激素 β链 C-末端肽 (β h CG-CTP)的免疫原性后 ,进一步观察其抗血清对 h CG生物活性的影响。利用蛋白质固相合成技术 ,将β h CG-CTP的两个 B细胞表位 (β8,β9)以及一个源自麻疹病毒融合蛋白的“通用”T细胞表位合成于一体 ,以此多肽免疫家兔 ,以 WHO的 β h CG-CTP疫苗标准品为对照 ,制备抗血清 ,利用小鼠子宫增重试验检测抗血清对 h CG生物活性的影响。结果 :该嵌合多肽免疫家兔后产生的抗血清原液、1∶ 1 0及 1∶ 5 0倍稀释时 ,能显著抑制 h CG诱导的小鼠子宫增重。结果表明 ,β h CG-CTP经分子改进后不仅免疫原性增强 ,且能在体内中和 h CG的生物学效应 ,可发展为人类免疫避孕法
After confirming that the molecular improvement can enhance the immunogenicity of human chorionic gonadotropin beta-chain C-terminal peptide (β h CG-CTP), the effect of antiserum on h CG biological activity was further observed. The two B cell epitopes of β h CG-CTP (β8, β9) and a “universal” T cell epitope derived from the measles virus fusion protein were synthesized using protein solid-phase synthesis, Rabbits to WHO β h CG-CTP vaccine standards for the control of antiserum, the use of mouse uterine weight gain test h antisera on h CG biological activity. Results: The chimeric peptides could significantly inhibit the hCG - induced uterine weight gain in rabbits when the antisera produced by rabbits were diluted 1:10 and 1:50. The results showed that β h CG-CTP not only enhanced the immunogenicity but also neutralized the biological effects of h CG in vivo, which could be developed into the human immunization contraceptive method